Compare Ascendis Pharma A/S (ASND) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs TORM plc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while TORM plc trades at $28.6 (market cap $3.01B). The key difference: Ascendis Pharma A/S is far larger — about 5.6× TORM plc's market cap, and TORM plc pays a 9.59% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TRMD | |
|---|---|---|
Market Cap | $16.78B | $3.01B |
Sector | Health | Technology |
52-Week High | $277.18 | $34.87 |
52-Week Low | $189.74 | $18.77 |
Enterprise Value | $17.15B | $3.89B |
Dividend Yield | — | 9.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
TRMD trades at $29.49 with a neutral daily change. The stock shows strong fundamentals with a P/E of 8.57, net income margin of 24.41%, and ROE of 15.62%, though recent Q1 2026 EPS missed expectations. Technical indicators are bearish overall, with support at $28 and resistance at $30. Recent news highlights strong Q1 2026 results and a dividend of $0.70 per share.
The outlook is positive with 100% analyst buy ratings and robust cash flow, but risks include earnings volatility and market sentiment. The stock offers value through dividends and growth potential, yet investors should monitor earnings consistency and macroeconomic factors affecting the tanker market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
